Division of GlaxoSmithKline PLC
Latest From ViiV Healthcare
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Janssen’s two investigational Ebola vaccines are among four new products recently granted fast-track review by the European Medicines Agency. GlaxoSmithKline and Viiv Healthcare are not disclosing the outcomes of accelerated assessment requests they have made.
ViiV Healthcare has asked the European Medicines Agency to accelerate its review of fostemsavir when the company files for pan-EU market approval of the product.
The European Medicines Agency is this week deciding whether GlaxoSmithKline’s planned EU marketing application for its BCMA-targeting therapy merits an accelerated assessment.
- Therapeutic Areas
- Infectious & Viral Diseases
- GSK Pfizer HIV
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Jerome Andries, CFO
John Pottage, MD, CSO & CMO
Gregory Reinaud, Head, Global Commercial Strategy
- Contact Info
Phone: (44) (0)20 8380 6200
980 Great West Rd.
Brentford, TW8 9GS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.